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Abstract
A systematic literature review was conducted to establish whether gender specific treatment
exists for patients with Chronic Obstructive Pulmonary Disease (COPD), specifically, women
with (COPD). The PICO question developed for this review is as follows: In women with
confirmed diagnoses of COPD, does gender-specific treatment, compared to standard treatment,
impact the frequency of exacerbations? Could the number of COPD exacerbations in women be
reduced by incorporating interventions designed with (female) gender in mind? Four databases
were included in the search: CINAHL, Pubmed, Medline, and Nursing and Allied Health.
Articles included addressed gender differences in relation to the disease process, medication(s),
or overall treatment. There were 16 articles selected for this review. This analysis found gender
differences with regards to lung development, disease presentation, diagnosis, exacerbations, and
prognosis. A definitive answer to the PICO question was not found from this systematic review,
yet future research is warranted to determine whether gender differences to exist with regards to
treatments/interventions in patients with COPD. Recommendations for practice, research,
education, and policy are based on articles included within the review.
Keywords: Chronic obstructive pulmonary disease, COPD, women or female, gender
differences, exacerbations
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Reducing Disease Exacerbation in Women with Confirmed COPD: A Systematic
Literature Review
Chronic obstructive pulmonary disease (COPD) is the third most common cause of death
in the United States (US) (Guarascio et al., 2013). In 2010, the cost of COPD in the US was
projected to be approximately $50 billion, which includes $20 billion in indirect costs and $30
billion in direct health care expenditures (Guarascio et al., 2013). COPD is a progressive disease
and the cost of treating this illness is not decreasing in the US, however, earlier diagnosis and
medication advancements can add years to patient lives (Guarascio et al., 2013). COPD was
previously considered a male dominant disease process, but current data reveals women with
COPD now exceed men in hospitalization and death (Celli et al., 2010). Celli et al. (2010)
designed a study a three-year study, -Toward a Revolution COPD (TORCH), to evaluate sex
differences related to risk of death from COPD, TORCH results indicate women were 16 percent
less likely to die from the disease, but when covariates such as body mass and airflow
obstruction were corrected, the results between genders were equal. Data indicates that with each
progressive stage of COPD, as defined in the GOLD guideline, the cost to treat patients increases
(Guarascio et al., 2013). Patients with stage I COPD experienced the lowest direct cost of $1681
per patient per year, stage II patients will incur $5037 per patient per year, and those in stage III
had the highest cost of care, $10,812 per patient per year (Guarascio et al., 2013).
COPD varies in etiology. It is a progressive disease of airway obstruction caused by
inflammation; which narrows airways, increases mucus production, and subsequently creates a
cough; all of which can create dyspnea for the individual (Breyer et al., 2011). Primary risk
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factors for COPD include cigarette smoking and biomass. The disease process included
pulmonary and non-pulmonary manifestations, with dyspnea and cough as the most prevalent
symptoms in patients with COPD (Breyer et al., 2011). After a diagnosis of COPD, a referral for
pulmonary function testing to establish baseline spirometry values is a prudent next step (Breyer
et al., 2011).
Early diagnosis is key in controlling and limiting progression of COPD; once thought to
be impossible (Criner et al., 2019). Smoking cessation, vaccinations, supplemental oxygen for
hypoxemic patients, and lung volume reduction surgery in selected patients all improve survival;
smoking cessation also attenuates disease progression (Criner et al., 2019). Patients with COPD
experience episodes of increased symptomology that may necessitate hospitalization and intense
management of the illness at times (Criner et al., 2019). Secondary infections have their own
symptoms and may worsen existing disease (Criner et al., 2019), further increasing risk for an
exacerbation and need for hospitalization.
Emerging research suggests that women and men may progress differently through the
disease process (Celli et al., 2011; Criner et al., 2019). Research up until this point has primarily
focused on male with COPD (Grabicki et al., 2019) It is now recognized that COPD in women is
a major healthcare problem worldwide (Cote & Chapman, 2009). This may be due to increasing
rates of cigarette smoking in women, hazardous work environments, and/or wood smoke
exposure. Women’s airways are also smaller than men’s and it is possible women require less of
a caustic agent to damage their lungs or that the exposure to caustic agents is higher due to their
smaller airways (Martinez et al., 2012). The burden of COPD among women continues to grow;
the number of women dying from COPD in the US now exceeds that of men (Celli et al., 2010).
Clinical Question
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The following PICO question was developed to guide the systematic review of the
literature: In women with confirmed diagnoses of COPD (P) does gender-specific treatment (I)
compared to standard treatment (C) impact the frequency of exacerbations (O)? The research
question included a comparison group, as it was hypothesized that specific treatment by gender
may offer better health-related quality of life (HRQoL) and disease management in women
affected by COPD in addition to lessening the frequency and number of exacerbations.
Clinical Significance for Advanced Practice
Advanced practice providers (APP) readily see female patients with COPD in the primary
care clinic setting. Recommending the best possible medication or treatment regimen for this
subpopulation allows the opportunity to educate and facilitate a COPD care plan that will not
only promote better HRQoL, but also fewer COPD exacerbations.
Methods
A systematic literature review was done to produce current articles regarding the PICO
question cited above. Electronic databases were utilized to find relevant materials related to
treatment of women with COPD, to evaluate whether gender-specific or standard treatment
affected reduced symptoms of disease, and if those treatments decrease the number of
exacerbations women experience. The primary focus of this review is whether or not there is a
difference when gender is considered in the treatment of COPD.
Database
The databases searched for this review were the Cumulative Index of Nursing and Allied
Health (CINAHL), PubMed, Medline, and Nursing and Allied Health. Restrictions added to the
search were that articles had to be full text, printed in the English language, and peer reviewed.
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The articles had to be published between the years 2010 and 2020 assuring currency of research.
The initial search results can be viewed in the Appendix, Table 1.
Abstraction Process
The abstraction process limited the key words to Chronic Obstructive Pulmonary
Disease, COPD, women, treatment, exacerbations, gender differences, interventions, outcomes,
and female. The initial search yielded 9071 articles (see Table 1 in the Appendix). Article criteria
was further reduced based on the following words; Chronic Obstructive Pulmonary Disease,
women or female, gender differences, and exacerbations. This brought the article total to 38.
Results can be viewed in the Appendix, Table 2.
Search Strategies
Thirty-eight articles were reviewed based on the abstract and content to decide if they fit
the purpose of the literature review. They were excluded if they did not address the central
themes related to gender comparison or female treatment related to COPD exacerbations. If a
gender difference was noted in the article with regards to lung development, risk factors, testing,
diagnosis, or treatment, the article was included in the analysis. Exclusion versus inclusions
criteria and findings can be viewed in can be viewed in the Appendix, Table 3.
Literature Review Process
There were 16 articles included in this literature review. Research on COPD in females is
relatively new. Previous research has foculsed on the male population. Similarities among the
articles in the review suggest that differences do exist between genders with relation to COPD
(Augusti et al., 2010; Breyer et al., 2011; Celli et al., 2011; Kohler et al., 2013, Martinez et al.,
2012). Only one article clearly addressed the clinical question regarding gender and treatment
and its effect on disease exacerbation (Celli et al., 2011). No research was found to support the
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use of specific medication protocols or treatment plans for females with COPD (Celli et al.,
2011) Several articles offer partial answers to the question and will help steer future research.
Further data related to these articles can be found in the Appendix, Table 4.
Study Characteristics
Of the 16 studies researched, two were level I studies, one study was a level II study,
twelve were level III studies, and one was a level IV study (see Table 4 in the Appendix). The
level I studies consisted of two systematic reviews. The level II study looked at laboratory data
for comparison. The level III studies consisted of trials, measurement comparison, trend
comparison, straight-forward comparison, data review, cross-sectional study, randomized control
study, and multiple regression analysis. The single level IV study utilized a multi-variate logistic
regression model to identify proteins of interest (Kohler et al., 2012). The population samples
included both men and women with COPD. All studies had more male participants than female
participants. One study used veterans who had developed COPD and hospital admissions rates to
assess for gender differences (Fuhrman et al., 2011). Only one of the studies, (Wedzicha et al.,
2019) specifically addressed, medications as an intervention/treatment, and its effect related to
gender. Wedzicha et al. (2019) did not find the results differed between genders with regard to
medication used to treat COPD. The medication classes in this study were a combination inhaled
long acting bronchodilator and corticosteroid.
Definitions:
Six-minute walk: The distance that is walked in a 6-minute period. There are predicted normal
values for the six minute-walk based on age and sex. This screening test is predictive of
functional status (Torres et al., 2011).
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Biomass: Fumes related to household work, occupationally related, or woodsmoke (Cote &
Chapman 2009).
Bronchoalveolar lavage cell proteome: A proteome obtained during a bronchoalveolar lavage
(BAL). BAL is a lung fluid sample obtained via normal saline inserted into the lung and drawn
out carrying lung fluid with it (Kohler et. al., 2013)
BODE index: An index that considers several criteria to estimate a survival rate in years. The
criteria are FEV1 % of predicted, six-minute walk distance, mMRC dyspnea scale, and BMI
(Cote & Chapman, 2009).
DOSE index: (D) dyspnea, (O) airflow obstruction, (S) current smoking status, (E) frequency of
exacerbations in the past year (Wang et al., 2017).
FEV1: The amount of air a patient can expel from his/her lungs in one second. This maneuver is
done during spirometry testing, also referred to as pulmonary function testing. This test produces
a predicted value for a gender and age. The test assesses lung function based on what percent a
patient scores in relation to the predicted lung function for age and gender. Lung function in
those with COPD, elicits reduced scores, in relation to predicted FEV1 %. The guideline for a
positive diagnosis of COPD is achieving a score of 80% (or less) of predicted. 80% of the
predicted lung function would suggest mild disease; 50% to 79% suggests moderate disease, 3049% suggests severe disease, and less than 30% is considered very severe or end stage disease
(Cote & Chapman, 2009).
Lung Information Needs Questionnaire (LINQ). This iinstrument can be used as a baseline for
establishing information needs/patient understanding of COPD and its treatment for comparison
with future evaluations (Wakabayashi et al., 2019).
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mMRC: Modified Medical Research Council Dyspnea scale is used to distinguish severity of
dyspnea in respiratory illness (Cote & Chapman, 2009).
SGRQ: St. George’s Respiratory Questionnaire is utilized in those with obstructive lung
diseases. It measures disease impact on the patient’s overall health, daily activities, and
perceived well-being (Celli et al., 2011).
TORCH: Toward a Revolution in COPD Health. This was a 3-year study to determine sex
differences in survival causes of death, and patient-centered outcomes in a 3-year period (Celli et
al., 2011).
Results
Biomarkers
There are differences between men and women at a cellular level. Kohler et al. (2012)
studied the gender differences of bronchoalveolar lavage cell proteome in COPD patients.
Kohler et al. (2012) found there are changes that occur in female COPD patient’s proteomes that
do not occur in male patients proteomes. It was learned that these changes also do not happen in
female non-smokers (Kohler et al., 2012). Kohler et al. (2012) demonstrated that there is a
specific change in female smokers who develop COPD. The differences identified in these
studies further support that gender differences exist in COPD phenotypes and diagnosis and
treatment on the basis of gender warranting further investigation.
De Torres, et al. (2011) did a pilot study looking at biomarker levels in a cohort of COPD
patients. Of these patients 80 were smokers without COPD (40 male and 40 female) and 152
were stable COPD patients (76 male and 76 female), with similar airflow obstruction at time of
study. De Torres, et al. (2011) found there was statistical difference in level IL-6, IL16, and
VEGF levels between women and men with COPD (de Torres et al., 2011). The researchers
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acknowledge that this study needs to be replicated to further support or refute these preliminary
findings.
Breyer et al. (2011) studied the role of leptin in relation to gender differences in COPD.
They found women with COPD had an increase in leptin compared to men with COPD and
healthy females without COPD. Leptin secretion increased with increasing fat mass to a greater
extent in COPD women when compared with their male counterparts, supporting the hypothesis
of gender-specific leptin metabolism in COPD (Breyer et al., 2011). It is unknown at this time if
increased weight carries an increased risk of symptoms in COPD patients. What is known is
significant: There is a change in leptin metabolism in women with COPD.
Factors Impacting Gender Response to COPD
Potential variable related to sex differences in tobacco susceptibility causing COPD
include differences in metabolism, hormonal influences, lung anatomy, inhalation technique, or a
dose exposure because women’s lungs are smaller than men’s (Criner et al. 2019). Wood smoke
exposure is possible in homes that utilize wood as a heat source. It is known that cigarette
smoking is the leading contributor of COPD causes (Criner et al., 2019). Airway hyperresponsiveness in men is associated with allergies and asthma, whereas airway hyperresponsiveness in women it is associated with smoking indicating that airways react differently
in men and women (Criner et al., 2019). It is known that women with COPD are frequently
initially misdiagnosed with asthma and not tested with spirometry until after their first
hospitalization. Bade et al. (2019) suggest that prior to a hospitalization, women were less likely
to have pulmonary function testing or be treated with antimuscarinic or combined long-acting
bronchodilator/inhaled corticosteroid inhalers. This demonstrates the delay that happens in the
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diagnosis of COPD and treatment in women. It is now recognized that early diagnosis is proven
to slow disease progression (Bade et al., 2019).
Readmission is strongly influenced by comorbidities, suggesting that individualized and
comprehensive case management may reduce readmission risk for women and men. (Bade et al.,
2019) Cote et al. (2009) considered the unique findings of two separate COPD related studies
conducted by Miravitlles et al. (2006) and Chapman et al. (2001). These two studies, essentially
equal on all accounts, were developed into cases for providers to review for purposes of making
a COPD diagnosis. Women with COPD were diagnosed 11-16% less correctly than men with
COPD by the participating providers. However, when spirometry was utilized in the given cases,
the primary care providers (PCPs) were less likely to miss a diagnosis of COPD in both men and
women.
Gender Effects of Medications Approved for COPD Treatment
A study by Wedzicha et al. (2019) reviewed the combination medication
indacaterol/glycopyronium, which is a long-acting beta agonist (LABA) and an inhaled
corticosteroid, and whether gender differences were found when taking this medication
regularly. Although there were gender differences in baseline characteristics between men and
women with COPD in the Wedzicha et al. (2019) study, indacaterol/glycopyronium
demonstrated similar trends for exacerbation, prevention, and lung function improvement in men
and women with moderate-to-very severe COPD. In addition to the above, Wedzicha et al.
(2019), compared indacaterol/glycopyronium against the drug combination
salmeterol/fluticasone, which is also a LABA/corticosteroid combination medication. Both of
these medications are administered via a multi-dose inhaler. The indacaterol/glycopyronium dose
was 110/50 ug once daily and the salmeterol/fluticasone dose was 50/500 twice daily. Although,
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the prior medication combination would be more convenient, it didn’t offer an advantage of
improving COPD outcomes in women. (Wedzicha et al., 2019)
Barriers to Care/Education
Significant gender-related differences in the perception of COPD healthcare delivery
exist, revealing an opportunity to better understand what influences attitudes and to improve care
for both men and women with COPD (Martinez et al., 2012). Martinez et al. (2012) showed that
women generally made less money, were diagnosed later, and felt they had a harder time
reaching a provider to discuss COPD care needs. Based on questionnaire results, it appears that
there is a gap in education for female patients (Martinez el al., 2012). This occurred even though
the availability of physicians, rehabilitation services, and insurance were similar to that of men.
Wakabayashi et al. (2019) explored gender differenced in COPD knowledge utilizing the LINQ.
They found that females displayed significantly higher information needs than men. No
difference was seen between sexes on subjects of knowledge, medicine, smoking, and exercise
domains; the gender difference involved knowledge about avoidance of disease exacerbation.
Disease State and Dyspnea Disconnect
The main theme throughout the articles in this review is that female patients report
greater dyspnea than is expected for measured lung function. The Evaluation of COPD
Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) was a large multi-country,
multi-patient study conducted in 46 centers. This study was designed to define COPD
phenotypes and identify biomarkers to aid in the prediction of disease progression (Augusti, et
al., 2010). The severity of airflow limitation in COPD patients was poorly related to exacerbation
reported in the year prior to the study (Augusti et al., 2010). Celli et al. (2011) found that even
when correcting for degree of airflow obstruction, women report more anxiety and depression,
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worse symptoms, lower exercise capacity, more airway hyperresponsiveness, and worse HRQoL
than men. This could be related to smaller airways and disease progression. Much less is known
about any sex differences in mortality and the factors that may affect it in the patients with
COPD (Celli et al., 2011).
Exacerbations and Hospitalizations Related to Exacerbations
Acute exacerbation of COPD (AE-COPD) are major events in the disease course,
especially when the necessitate a hospitalization (Fuhrman et al., 2011). Grabicki et al. (2019)
found that women had significantly more exacerbations than men. In fact, they observed that
women experienced at least two to four more exacerbations in a two year interval compared to
men who experienced exacerbations in the same time interval. Overall women have fewer
comorbidities as a whole (Bade et al., 2019). Comorbidities can exacerbate COPD symptoms and
in some cases cause a need for hospitalization. There is a correlation for both men and women
regarding exacerbations, but it is slightly stronger for woman (Fuhrman et al., 2011). Fuhrman et
al. (2011) found in a French study that COPD exacerbations were increasing for women and
follow illness trends such as influenza.
Prognosis of COPD
Prognosis is typically based on how well the treatment works for the patient, whether or
not the patient quits smoking, and how effectively they are with self-management (Wang et al.,
2017). The DOSE index is a good predictor of patient prognosis (Wang et al., 2017). Wang et al.
(2017) conducted an exploratory study that demonstrated higher physical activity, higher BMI,
and female sex were important factor for lowering the DOSE index, thereby offering ways that
might improve the prognosis of patients with COPD.
Gaps in Literature
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The primary gap with regards to gender-based COPD treatment currently is trialing
medications head-to-head with specific care plans that are developed by patient gender. This is
an area where further research is needed in order to impact the frequency and severity of COPD
exacerbations and outcomes for women.
Discussion
This systematic literature review focuses on whether gender-specific versus standard
treatment could reduce exacerbations in women with COPD. Over a five-year study period
Grabicki et al. (2019) attempted to evaluate whether significant differences could be found
between Polish women and men suffering from COPD, with regard to clinical presentation,
pulmonary function test results, comorbidities, and prognosis. Grabicki et al. (2019) found
gender differences existed for exacerbations, comorbidities and prognosis. Women had more
exacerbations, less comorbidities on average (although a wider distribution of comorbidities),
and worse prognosis with less cigarette exposure than their male counterparts (Criner et al.,
2019). Agusti et al. (2010) found that when subjects of similar age, and gender were analyzed by
BODE scores, females reported less smoking exposure and more exacerbations than their male
counterparts. In stable COPD patients with similar airflow obstruction, there are gender
differences in plasma biomarker levels and in the association between biomarker levels and
important clinical or physiological variables (de Torres et al., 2011). de Torres et al. (2011)
acknowledges that further research is needed beyond their pilot study to further validate their
findings. de Torres et al. (2011) suggest their study can serve as a hypothesis for future research.
Interestingly, in the de Torres et al. (2011) study, there was no difference in the plasma
biomarker levels in smokers without COPD.
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Women achieve peak lung function earlier than males (15 years versus 22 years) (Criner
et al., 2019). This is of significance because women are more likely to develop COPD with less
tobacco exposure than men, thus suggesting a developmental component difference in this
disease (Criner et al., 2019). Potential causes of sex differences in tobacco susceptibility include
differences in metabolism, hormonal influences, lung anatomy, inhalation technique, or a dose
exposure because women’s lungs are smaller than men’s (Criner et al., 2019). Airway
hyperactivity in men is associated with allergies and asthma, whereas in women it is associated
with smoking; indicating airways react differently in men and women (Cote & Chapman, 2009).
Women tend to report a lesser pack-year history than men diagnosed with COPD (Criner et al.,
2019). While studies are varied on the subject of smoking, newer literature suggest women are
more susceptible to the harmful effects of smoking (Criner et al., 2019), possibly due to
anatomical structure. Women’s smaller airways may expose them to a larger quantity the
chemicals in cigarette smoke (Cote & Chapman 2009; Criner et al., 2019).
Women tend to be under-diagnosed with COPD (Ford et al., 2014). Use of spirometry
testing reduces under-diagnosing and in many instances PCPs just fail to test (Cote & Chapman,
2009). It is harder to overlook an abnormal test result, especially when they align with a COPD
diagnosis.
Currently there is limited research on gender-based treatment. Wedzicha et al. (2019)
post-hoc analysis in the FLAME study, found IND/GLY did not out-perform SFC for
exacerbation prevention in women with COPD, despite gender differences in baseline
characteristics in lung function. Women reported greater improvement in quality of life with
IND/GLY (Wedzicha et al., 2019), yet this assertion was not supported by decreased
exacerbations or disease progression (Wedzicha et al., 2019). However, (Wedzicha et al., 2019)
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found IND/GLY didn’t worsen the disease. There appears to be a disconnect as women do not
report the same symptom relief or increase in (HRQoL). This does not mean that men and
women should be treated the same or different. There just isn’t enough information to make this
determination with what we currently know about this disease and its impact on female gender.
Medication regimens are tailored based on disease characteristics and patient symptomology.
Non-pharmacologic therapies such as pulmonary rehabilitation should be available to all patients
with COPD. It has been shown that the efficacy of both oxygen therapy and exercise therapy
may vary according to gender (Cote & Chapman 2009).
Women report more dyspnea and less frequency of cough and phlegm than men with
same disease state (August et al., 2010). Common comorbidities experienced concurrently with
COPD by women include heart disease, diabetes, stroke, anxiety, depression, obesity,
osteoporosis, and arthritis (Augusti et al., 2010). While Augusti et al. (2010) could list
differences in comorbidities it is unknown what causes the differences COPD symptoms in
relation to them. It could encompass female anatomy, comorbidities, and/or possibly treatment
effects. Breyer et al. (2011) discusses a study done by Ahonen et al. (2008) that demonstrated
decreased plasma concentrations of the anti-inflammatory adiponectin in women and increased
CRP in men that may contribute to symptom differences in the etiology of COPD between
genders. This is why it is so important to further evaluate women and the various etiologies and
effects of COPD has on their health and HRQoL.
When compared to men, women frequently use an emotion-focused coping strategy, a
response characterized by such emotions as anxiety and depression (Martinez et al., 2012).
Anxiety and depression may be contributing to the feeling dyspnea witnessed at increased rate in
women in relation to the disease process. Martinez et al. (2012) found that as sources of disease
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education for patients with COPD expand, women are now obtaining information about their
disease from online support groups, and fewer women are obtaining disease information from
their physician as compared to how men gain insights into and understanding COPD. This
related to the women feeling that the diagnosis was initially delayed and that contact with their
provider was difficult. This fact in itself creates potential for anxiety in a patient male or female.
When women are compared to men with the same state of disease and comorbidities, the
BODE is a good indicator of mortality (Wang et al., 2017) The BODE index considers patient’s
body mass index, airflow obstruction (from spirometry testing), dyspnea, and exercise capacity
(Wang et al., 2017). Wang et al. (2017) asserts, the DOSE index may be a better indicator for
overall prognosis of COPD.
COPD is a chronic illness that is partially self-managed (Wakabayashi et al., 2019). For a
patient to successfully manage COPD in the home setting and avoid the need for medical
intervention (up to and including hospitalization), education is key (Wakabayashi et al., 2019).
Patients need to have knowledge about disease management, who to contact during an
exacerbation or crisis, and medical coverage. Despite reporting similar access to healthcare
insurance, physicians, and pulmonary rehabilitation, more women than men reported insurance
as a barrier to at least one aspect of their care (Martinez et al., 2012). Patients with early stage to
mild COPD are not perceived as high risk and subsequently might not receive adequate selfmanagement education, and this may explain why the total LINQ score was correlated with
FEV1, and percent predicted (Wakabayashi et al., 2019). Studies have found that women require
more education about self-management (Martinez et al., 2012; Wakabayashi et al., 2019). This
suggest that for female COPD patients, more exacerbations and emergency visits may occur due
to a lack of education and that action plans might not be executed correctly (Wakabayashi et al.,
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2019). Wakabayashi et al. (2019) findings demonstrate why it is important to routinely assess
cognitive function of patients at appointments. It is necessary to ensure the capacity of the patient
to utilize information given about disease, follow up, and requirements for self-management.
Strengths and Weaknesses Associated with Review Findings
The strength of the research is yet to be fully understood. Utilization of measurement
tools and devices to gauge disease progression and dyspnea over time is a big first step. The
main weakness is the inability to draw any concrete conclusion on how to treat women with
COPD in regard to symptom management and/or exacerbations of the disease process. This is
primarily due to a lack of studies to draw evidence from in which we should base our practice
decisions. Repeated studies to confirm results and research involving gender specific studies will
strengthen findings that then in turn can be used in the practice setting in the future.
Recommendations for Clinical Practice
The PCP should work in collaboration with a pulmonologist to manage female patients
with COPD. Reviewing medications, controlling various comorbidities, providing vaccinations,
and smoking cessation education and treatment if needed are the hallmarks of the PCP’s role
with this patient. The PCP should always review the level of dyspnea patients with COPD are
experiencing along with their ability to manage tasks of daily living. Even with this single focus,
the PCP may be able to assist this patient in avoiding AE-COPD.
Recommendations for Research
There is a need for repeat studies involving medications available for managing patients
with COPD. This needed research should consider gender as a way to tailor medications and
treatments to best serve the female population. Perhaps interventional research, such as ways to
better communicate treatment options with female patients who are experiencing COPD/COPD
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exacerbations, will increase knowledge surrounding disease process and ultimately improve
outcomes and reduce exacerbations.
Recommendations for Education
PCPs should remain current regarding best practice related to females with COPD.
Understanding how comorbidities affect the patient may assist in primary care appointments and
help patient reduce AE-COPD. Patients need to know what to monitor in relation to COPD,
proper administration of prescribed medications and treatments, how to treat symptoms of
disease at home, when to call the PCP for assistance, and when they need to seek emergency
care. These topics are a few key points to assist in successful disease management at home.
Women require additional education to be successful with self-management (Martinez et al.,
2012; Wakabayashi et al., 2019).
Recommendation for Policy
There should be further efforts to establish health policy once it is known and better
understood how the role of gender impacts treatment of COPD. This review did not produce any
QI measures. This is something that could be researched in a future review or study. Health
policy should focus on issues surrounding readmission after exacerbations and reducing
exacerbations overall.
Conclusion
This systematic literature review was able to discern several differences between genders
in relationship to COPD. Unfortunately, the initial PICO question was not able to be answered
by the research findings contained within this systematic review, however it was a productive
start for this subject and additional research should be forthcoming. There is emerging evidence
that COPD in women is increasing and will be a burden to the healthcare system going forward.
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Women are more susceptible to developing COPD possibly due to the anatomy of their smaller
airways or lungs being fully developed at the time they start smoking (usually around 15 years of
age). Regardless of the reason, women require less exposure to cigarette smoke than men to
develop COPD. Currently there is a lack of research on pharmacological and nonpharmacological treatment specifically for women. Due to this omission, the initial question
asked in this systematic review cannot be answered but strongly advocates for a need for
additional research. Women with COPD need more education about this disease to aid with their
plan of care, the ability to self-manage, and avoid exacerbations. PCPs need to help manage
comorbid conditions effectively as poor control of these conditions can lead to increased COPD
symptoms and AE-COPD which can lead to the unfortunate outcome of hospitalization.
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The clinical manifestations of COPD are
highly variable, and the degree of airflow
limitation does not capture the
heterogeneity of the disease.

48,888
Veterans
(4%
women)

IV

Created and
combined
sex-stratified
multivariate
logistic
regression
models to
identify
associations

NA

Before hospitalization,
women were less likely
to have pulmonary
function testing (76%
vs. 78%; P = 0.01) or
be treated with
antimuscarinic (43% vs.
48%) or combined
long-acting
bronchodilator/inhaled

This study suggests differences between
women and men hospitalized for COPD
regarding presentation, evaluation, and
management. Readmission is strongly
influenced by comorbidities, suggesting
individualized and comprehensive case
management may reduce readmission risk
for women and men with COPD.
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exacerbatio
ns and how
they
differed by
sex.

Breyer, M.-K., Rutten, E. P.,
Vernooy, J. H., Spruit, M.
A., Dentener, M. A., & al.,
e. (2011, July). Gender
differences in the adipose
secretome system in chonic
obstructive pulmonary
disease (COPD): a pivotal
role of leptin. Respiratory
Medicine, 105(7), 10461053.

To
investigate
gender
related
differences
in the
adipokine
metabolism
in relation
to systemic
inflammato
ry
biomarkers
in clinically
stable
subjects

with 30-day
readmission.

91 COPD;
35 Control
(no COPD)

II

Lung
function
measurement
for BMI with
COPD
subjects

corticosteroid (61% vs.
64%) inhalers. Women
were more likely to
receive nicotinereplacement therapy
(all P < 0.01). Women
had shorter length of
stay (median days, 2 vs.
3; P = 0.04) and lower
30-day readmission rate
(20% vs. 22%; P =
0.01). In adjusted
models including both
sexes, age,
antimuscarinic use,
comorbidities, and
diagnosis of drug or
alcohol use were
associated with
readmission; there was
no association with sex
and readmission risk.
NA

The COPD group was
characterized by
increased levels of
CRP, IL-6, and Leptin.
Plasma adiponectin and
resistin concentrations
were not different
between the groups.

In men with clinically stable COPD,
leptin adiponectin and resistin appear to
be physiologically regulated while in
women leptin metabolism is altered.
Leptin secretion is increased in COPD
women when compared to healthy
women and compare to COPD men, and
to a greater extent in
overweight women with COPD.
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Celli, B., Vestbo, J.,
Jenkins, C. R., Jones, P. W.,
Ferguson, G. T., & al., e.
(2011, February 1). Sex
differences in mortality and
clinical expressions of
patients with chronic
obstructive pulmonary
disease. American Journal
of Respiratory and Critical
Care Medicine, 183(3), 317322.

Criner, G. J., Martinez, F. J.,
Aaron, S., Agusti, A.,
Anzueto, A., & al., e. (2019,
January). Current
controversies in chonic
obstructive disease. A report
from the global initiative for
chronic obstructive lung
disease scientific
committee. Annals of the

with
COPD.
Determine
sex
differences
in survival,
causes of
death, and
patientcentered
outcomes
in the 3year
Toward a
Revolution
in COPD
Health
(TORCH)
study.

Review of
current
standards,
informatics
, and
guidelines
related to
COPD

1,481
women and
4,631 men
with COPD

III

NA

A trial
comparing
salmeterol, 50
μg, plus
fluticasone
propionate,
500 μg, twice
a day and each
component
individually.

At baseline, women
were younger (63 vs. 66
yr.), had higher
FEV1 (47% vs. 44%
predicted), and worse
St. George's
Respiratory
Questionnaire (51.3 vs.
48.7) and Medical
Research Council score.
During the study, 707
(15.3%) men and 168
(11.3%) women died.
After adjusting for
differences in baseline
factors, the risk of
dying was 16% higher
in men than in women;
however, this was not
statistically significant
(hazard ratio 1.16 [95%
CI, 0.98–1.39]). Causes
of death were similar in
women and men.
Exacerbation rate was
25% higher in women
than in men.

Women enrolled in TORCH had a lower
mortality rate than men but similar causes
of death. The risk of dying was similar in
women and men after adjusting for
important baseline variables. Women
reported more exacerbations, and worse
dyspnea and health status scores than
men.

NA

I

NA

NA

Women do vary from
men for COPD risk for
development when
exposed to or partaking
in smoking. Women
are more susceptible.

More research is needed to decipher best
treatment options for women.
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American Thoracic Society,
16(1).
de Torres, J. P., Casanove,
C., Pinto-Plata, V., Varo,
N., P, R., & al., e. (2011).
Gender differences in
plasma biomarker levels in a
cohort of COPD patients: a
pilot study. PLoS one, 6(1).

Explore
gender
differences
in plasma
biomarker
levels in
patients
with COPD
and
smokers
without
COPD.

80 smokers
without
COPD (40
males, 40
females)
and 152
stable
COPD
patients (76
males, 76
females)
with
similar
airflow
obstruction.

III

Measurement
of plasma
biomarkers

NA

The plasma biomarkers
level explored were
similar in men and
women without COPD.
In contrast, in patients
with COPD the median
value in pg/mL of IL-6
(6.26 vs 8.0, p = 0.03),
IL-16 (390 vs 321,
p = 0.009) and VEGF
(50 vs 87, p = 0.02)
differed between
women and men.
Adjusted for smoking
history, gender was
independently
associated with IL-16,
PARC and VEGF
levels. There were also
gender differences in
the associations
between IL-6, IL-16
and VEGF and
physiologic variables
that predict outcomes.

In stable COPD patients with similar
airflow obstruction, there are gender
differences in plasma biomarker levels
and in the association between biomarker
levels and important clinical or
physiological variables. Further studies
should confirm our findings.

Ford, E. S., Mannino, D.
M., Wheaton, A. G.,
Presley-Cantrell, L., Liu, Y.,
& al., e. (2014, April).
Trends in the use,
sociodemographic
correlates, and
unertreatment of
prescription. PLos One,
9(4).

Examine
trends in
prescriptio
n
medication
s for COPD
among
adults in
the US
from 19992010

1426

III

6 national
surveys

N/A

Medications changed
markedly from 1999200 to 2009-2010.
Many adults with
COPD did not report
having recommended
prescription
medications.

Increased need for additional research to
discover barriers to patients filling and
using prescription medications.
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Fuhrman, C., Roche, N.,
Vergnenegre, A., Zureik,
M., Chouaid, C., & al., e.
(2011, April). Hospital
admissions related to acute
exacerbations of chronic
obstructive pulmonary
disease. Respiratory
Medicine, 105(4), 595-601.

We
examined
temporal
trends in
AE-COPDrelated
hospital
admissions
in France
between
1998 and
2007.

Data were
obtained
from the
French
national
hospital
discharge
database
for patients
aged at
least 25
years. AECOPD was
identified
with both a
“narrow”
and a
“broad”
definition,
according
to the
position
(primary or
associated)
of
diagnoses,
in order to
ensure
robustness.

III

Data were
obtained from
the French
national
hospital
discharge
database for
patients aged
at least 25
years. AECOPD was
identified
with both a
“narrow” and
a “broad”
definition,
according to
the position
(primary or
associated) of
diagnoses, in
order to
ensure
robustness.

NA

In 2007, among adults
aged 25 years or more,
the crude AE-COPDrelated admission rates
were 23/10000 in men
and 10/10000 in women
using the narrow
definition. Using the
broad definition, these
rates were respectively
38 and 16/10000. With
the narrow definition,
the annual number of
AE-COPD-related
admissions increased
by 38% between 1998
and 2007, while inhospital lethality decrea
sed from 7.6% to 6.0%.
The proportion of male
patients decreased from
72% to 68%. Similar
trends were found using
the broad definition.
The age-standardized
AE-COPD-related
admission rate
increased by 4.4% per
year in women and by
1.6% per year in men
with the narrow
definition, and by
respectively 3.8% and
1.2% with the broad
definition. A strong
seasonal pattern of
admissions for AECOPD was found,
matching that of
general practitioners

Hospitalization rates for AE-COPD have
increased in France in recent years,
especially among women. By contrast,
AE-COPD-related in-hospital lethality
has decreased.
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visits for influenza-like
illness.
Grabicki, M., KuznarKaminska, B., Rubinsztajn,
R., Brajer-Luftmann, B., &
Kasacka, M. (2019). COPD
course and comorbidities:
are there gender
differences? Advances in
Experimental Medicine and
Biology, 43-51.

The aim of
this study
was to
evaluate
significant
differences
between
women and
men
suffering
from
COPD,
regarding
clinical
presentatio
n,
pulmonary
function
test results,
comorbiditi
es, and
prognosis.

470
patients
with stable
COPD with
a history of
smoking
(152
women,
318 men,
mean age
65.5 ± 8.8
vs. 66.6 ±
9.4 years,
respectivel
y)

III

Measurement
of FEV1

NA

Women smoked less in
comparison to men
(30.4 vs. 41.9 packyears, p < 0.05),
showed more
exacerbations (2.5 vs.
1.7, p = 0.01), higher
forced expiratory
volume in 1 s
(FEV1%predicted), and
increased residual
volume/total lung
capacity (RV/%TLC),
but they had the same
intensity of dyspnea.
Women showed fewer
comorbidities, on
average, per patient (5.4
vs. 6.4, p = 0.002), but
had a higher prevalence
of at least seven
comorbidities per
patient (48.7% of
women vs. 33.0% of
men, p < 0.05). Women
also had a significantly
worse prognosis (4.6
vs. 3.1 BODE score, p
< 0.05) that correlated
with the number of
comorbidities (r = 0.33,
p < 0.01). In
conclusion, this study
strongly supports the
existence of different
gender phenotypes in
COPD, especially

The gender difference may indicate a
need for a targeted assessment and
management of COPD in women and
men.
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regarding
exacerbations,
comorbidities, and
prognosis.
Kohler, M., Sandberg, A.,
Kjellqvist, S., Thomas, A.,
Karimi, R., & al., e. (2013,
March). Gender differences
in the bronchoalveolar
lavage cell proteome of
patients with chronic
obstructive pulmonary
disease. Journal of Allergy
and Clinical Immunology,
131(3), 743-751.

Martinez, C., Raparla, S.,
Plauschinat, C., Giardino,
N. D., Rogers, B.,
Beresford, J., . . . Han, M.

In this
study the
soluble prot
eome of br
onchoalveo
lar
lavage cells
, primarily
consisting
of
macrophag
es, was
investigate
d with the
aim of
identifying
phenotypic
differences
in early
disease
developme
nt.

NA

Mo Using
data from a
nationwide
survey of

Data on
295 female
and 273
male

III

III

Twodimensional
difference gel
electrophoresi
s was used
for relative
quantification
of protein
levels, and
multivariate
modeling was
applied to
identify
proteins of
interest that
were
subsequently
identified by
means
of liquid
chromatograp
hy–mass
spectrometry.

NA

Surveys were
administered
to a
convenience

NA

Significant gender
differences were
unveiled, with
numerous alterations in
the bronchoalveolar
lavage cell proteome
occurring in female but
not male patients with
COPD. Specifically, a
subset of 19 proteins
provided classification
of female healthy
smokers from female
patients with COPD
with 78% predictive
power. Subsequent
pathway analyses
linked the observed
alterations to
downregulation of the
lysosomal pathway
and upregulation of
the oxidative
phosphorylation pathwa
y, possibly linking
dysregulation of
macroautophagy to a
female-dominated
COPD disease
phenotype.
Data on 295 female and
273 male participants
were analyzed. With
similar frequencies,

This investigation makes an important
contribution to the elucidation of putative
molecular mechanisms underlying
gender-based differences in
the pathophysiology of COPD, linking
alterations of specific molecular pathways
to previously observed gender differences
in clinical COPD phenotypes.
Furthermore, these results stress the
importance of the gender-specific search
for biomarkers, diagnosis, and treatment
in COPD.

Significant gender-related differences in
the perception of COPD healthcare
delivery exist, revealing an opportunity to
better understand what influences these
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(2012). Gender differences
in symptoms and care
delivery for chronic
obstructive pulmonary
disease. Journal of Women's
Health, 21(12), 1267-1274.

patients
with
COPD,
commissio
ned by a
patient
organizatio
n, the
COPD
Resource
Network–
National
Emphysem
a/COPD
Association
(NECA),
we
evaluated
potential
gender
differences
in
symptoms,
barriers to
care, and
sources of
information
about the
disease and
the effect
of
socioecono
mic and
emotional
factors on
patient
perceptions
of care.

participants

sample of
COPD
patients to
evaluate
perceptions
about
symptoms,
barriers to
care, and
sources of
information
about COPD.

women and men
reported dyspnea and
rated their health as
poor/very poor.
Although more women
than men reported
annual household
income <$30,000, no
significant gender
differences in frequency
of health insurance,
physician visits, or ever
having had spirometry
were detected. In
adjusted models (1)
women were more
likely to report COPD
diagnostic delay (odds
ratio [OR] 1.66, 95%
confidence interval [CI]
1.13-2.45, p=0.01),
although anxiety (OR
1.83, 95% CI 1.103.06, p=0.02) and
history of exacerbations
(OR 1.60, 95% CI 1.082.37, p=0.01) were also
significant predictors,
(2) female gender was
associated with
difficulty reaching one's
physician (OR 2.54,
95% CI 1.334.86, p=0.004), as was
prior history of
exacerbations (OR 2.25,
95% CI 1.214.20, p=0.01), and (3)
female gender (OR
2.15, 95% CI 1.10-

attitudes and to improve care for both
men and women.
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4.21, p=0.02) was the
only significant
predictor for finding
time spent with their
physician as
insufficient.
Torres, S. H., Montes de
Oca, M., Loeb, E., Mata, A.,
& Hernandez, N. (2011).
Gender and skeletal muscle
characteristics in subject
with chonic obstructive
pulmonary disease.
Respiratory Medicine,
105(1), 88-94.

a) to
evaluate
the gender
differences
of the
skeletal
muscle
characterist
ics in
COPD
patients b)
to explore
the gender
differences
of the
muscle
characterist
ics in
healthy
subjects
and c) to
explore the
differences
by gender
and COPD
status in
the skeletal
muscle
characterist
ics.

For
comparison
we studied
24 female
(61 ± 9
years) and
30 male
(65 ± 8
years)
COPD
patients
with
similar
disease
severity. In
addition,
healthy
subjects, 17
women
(58 ± 8
years), and
9 men
(57 ± 8
years) were
studied.

III

Pulmonary
function,
health status,
six minute
walk distance
test (6MWD)
and vastus
lateralis
muscle biops
y were
assessed.
Fiber type
proportion,
fiber type
cross
sectional area
(CSA),
capillary
counts, and
activity
of citrate
synthase (CS)
, 3hydroxyacylCoAdehydrogenas
e (HAD)
and lactatedehydrogenas
e (LDH) were
determined.

NA

Pulmonary function,
health status and
6MWD were similar in
male and female COPD
patients. Fiber type
distribution was similar
between women
(I = 42 ± 9%,
IIA = 39 ± 13%,
IIX = 19 ± 7%) and
men (I = 39 ± 13%,
IIA = 38 ± 9%,
IIX = 29 ± 10%) with
COPD, as well as CSA,
capillarity and enzymes
(CS 8.59 ± 1.6
vs.9.74 ± 2.6, HAD
9.03 ± 1.9 vs.
9.84 ± 2.5, LDH 124 ±
48 vs.
151 ± 68 μmol min−1 g−
1
). In normal subjects a
decrease in type IIX
fibers CSA was found
in women compared
with men (3703 ± 1478
vs. 5426 ± 1386 μm2,
respectively).

Female and male with COPD have
similar skeletal muscle characteristics; it
is possible that the disease blurs the
gender differences. On the other hand,
there seems to be fewer differences in
muscle characteristics between older men
and women, perhaps due to lower
male testosterone levels and physical
inactivity.
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Vestbo, J., Agusti, A.,
Wouters, E., Bakke, P.,
Calverley, P., Celli, B., . . .
Tal-Singer, R. (2014, May).
Should we view chronic
obstructive pulmory disease
differently after ECLIPSE?
A clinicical perspective
from the study team.
American Journal of
Respiratory and Critical
Care Medicine.

To
characteriz
e the
heterogenei
ty and
variability
of COPD
longitudina
lly.

2,164
patients
with
clinically
stable
COPD, 337
smokers
with
normal
lung
function,
and 245
neversmokers

III

Measured a
large number
of clinical
parameters,
lung function,
exercise
tolerance,
biomarkers,
and amount
of
emphysema
by computed
tomography.
All three
groups were
followed for
3 years.

NA

A striking heterogeneity
among patients with
COPD, with poor
correlations between
FEV1, symptoms,
quality of life,
functional outcomes,
and biomarkers.
Presence of systemic
inflammation was
found in only a limited
proportion of patients,
and did not relate to
baseline characteristics
or disease progression,
but added prognostic
value for predicting
mortality.
Exacerbations tracked
over time and added to
the concept of the
"frequent exacerbator
phenotype." Disease
course was very
variable, with close to a
third of patients not
progressing at all. Risk
factors for 3-year
change in both FEV1
and lung density were
assessed. For FEV1
decline, continued
smoking and presence
of emphysema were the
strongest predictors of
progression; club cell
protein was found to be
a potential biomarker
for disease activity. For
progression of

By following a large, well characterized
cohort of patients with COPD over 3
years, we have a clearer picture of a
heterogeneous disease with clinically
important subtypes ("phenotypes") and a
variable and not inherently progressive
course.
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emphysema, the
strongest predictors
were continued
smoking and female
sex.

Wakabayashi , R., Motegi,
T., & Kida, K. (2019,
January). Gender
differences in chronic
obstructive pulmonary
disease using the lung
information needs
questionnaire. Sage Open
Nursing, 5.

To
investigate
genderrelated
information
needs in
patients
with
chronic
obstructive
pulmonary
disease
(COPD)
using the
Lung
Informatio
n Needs
Questionna
ire (LINQ).

122

III

Cross
sectional
study.
Patients with
COPD
receiving
standardized
selfmanagement
education
including
information
regarding
disease
knowledge,
medications,
avoidance of
exacerbation,
smoking
cessation,
exercise, and
nutrition were
included.
Gender
differences
were assessed
by pulmonary
function tests,
6-minute
walking test,
modified
Medical

NA

Females displayed
significantly higher
information needs for
total LINQ score
(p < .001), avoidance of
exacerbation (p < .03),
and nutrition (p < .006).
Significant correlations
were seen between total
LINQ score and gender
(p = .001), forced
expiratory volume in 1
second, % predicted
(p = .003), and MiniMental State
Examination (p = .002)
for male patients. In
females, modified
Medical Research
Council dyspnea scale
was correlated with the
total LINQ score
(p = .04).

Behavioral differences in gender might
have an effect on the long-term
management of chronic diseases such as
COPD.
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Wang, L., Tao, Y.-X.,
Dong, X.-Y., Zhang, Q.,
Zheng, H., Zheng, Y.-S., . . .
Zhao, Y. (2017, February).
Demographic, health
behavioral, and selfmanagement abilities
associated with disease
severity among patients
with chronic obstructive
pulmonary disease.
International Journal of
Nursing Practice, 23(1).

To identify
the
association
between
demograph
ic
characterist
ics, health
behaviors,
selfmanageme
nt abilities,
and disease
severity
among
patients
with
chronic
obstructive
pulmonary
disease
(COPD).

100

III

Wedzicha, J. A., Singh, D.,
Tsiligianni, I., Jenkins, C.,
Fucile, S., Fogel, R., . . .
Kostikas, K. (2019, January
8). Treatment response to
indacaterol/glycopyrronium
versus

Evaluate
genderbased
differences
in the
FLAME
study

2557 men
and 805
women

I

Research
Council
dyspnea
scale, MiniMental State
Examination,
St. George's
Respiratory
Questionnaire
, and LINQ.
The DOSE
index was
assessed by
grade of
dyspnea (D),
airflow
obstruction
(O), current
smoking
status (S),
and
frequency of
exacerbation
in the last
year (E)

FLAME was
a 52-week
randomized
controlled
trial in
patients with
severe-to-

Selfmanagement
abilities were
assessed by the
COPD selfmanagement
scale. DOSE
index
associations
with
demographic
characteristics,
health
behaviors, and
selfmanagement
abilities were
examined with
multiple
regression
analysis.

In multiple regression
analysis, physical
activity, body mass
index, and gender were
negatively related to
DOSE index.

The study highlighted the importance of
physical activity, nutritional status, and
gender difference in managing disease
severity in COPD. Professional nurses
should develop individualized
intervention programs and specifically
increase physical activity for men and
poor nutritional status for patients with
COPD.

Bronchodilator
, inhaled
steroid
combination

Baseline characteristics
differed between
genders, with women
being younger, having
better lung function and
more often
experiencing ≥2

Although there were gender differences in
baseline characteristics, IND/GLY
demonstrated similar trends for
exacerbation prevention and lung
function improvement in men and women
with moderate-to-very-severe COPD and
a history of exacerbations compared with
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salmeterol/fluticasone in
exacerabting COPD patients
by gender: a post-hoc
analysis in the FLAME
study. Respiratory
Research, 20(1).

population
in terms of
baseline
characterist
ics and
efficacy
outcomes.

very-severe
COPD and a
history of
exacerbations
. In this posthoc analysis,
gender-based
baseline
differences
and treatment
outcomes
between
indacaterol/gl
ycopyronium
110/50 μg
once daily
(IND/GLY)
and
salmeterol/flu
ticasone
50/500 twice
daily (SFC)
were assessed
in terms of
rate of
exacerbations
, time-to-first
exacerbation,
lung function,
health status,
and rescue
medication
use.

exacerbations in the
previous year.
Compared with SFC,
IND/GLY treatment
was associated with
reductions in the
annualized rates of
moderate/severe
exacerbations (rate ratio
[95% CI]: 0.81 [0.730.91], 0.89 [0.74-1.07]
in men and women,
respectively). Similarly,
time-to-first
moderate/severe
exacerbation was also
delayed (hazard ratio
[95% CI]: 0.79 [0.700.89] and 0.76 [0.630.91] in men and
women, respectively).
Results were similar for
all
(mild/moderate/severe)
exacerbations.
Improvements in lung
function, health status
and rescue medication
use with IND/GLY vs
SFC were comparable
between men and
women. The smaller
sample size for women
may account for some
observed discrepancies
in treatment responses.

SFC. Small differences in the effects seen
between genders may be attributed to the
different sizes of the two groups and need
to be further evaluated in randomized
trials that are appropriately powered for
gender analysis.

